Here, we have sought to clarify the transcriptional regulatory mechanisms of CBFB and also examined the presence of the cell-autonomous compensation mechanisms after RUNX1-inhibition therapy in AML cells. This evidence concerns the gene CBFB and acute myeloid leukemia.